While various lymphocyte co-stimulatory molecules, such as major histocompatibility complex (MHC) class I and II molecules, CD83, CD86, and CD40 on CD11c+CD103+ DCs within tumours of mice treated with PAK4 inhibitors, did not show statistically significant differences compared to control mice, there were trend toward increased expression levels. This evidence concerns the gene CD40 and neoplasm.